ArticleJournal of clinical microbiology2008
Marked variability of BK virus load measurement using quantitative real-time PCR among commonly used assays.
Article in Journal of clinical microbiology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 2 syntheses or guidelines pooled it, 162 citations in OpenAlex.
- Serum and urine nucleic acid screening tests for BK polyomavirus-associated nephropathy in kidney and kidney-pancreas transplant recipients.The Cochrane database of systematic reviews · 2024Pooled it
- Interventions for BK virus infection in kidney transplant recipients.The Cochrane database of systematic reviews · 2024Pooled it
- Cellular immune response during BK polyomavirus infection in living donor kidney transplant recipients.BMC immunology · 2026Article
- The impact of FDA-cleared molecular solutions for BK polyomavirus quantitation.Journal of clinical microbiology · 2025Review
- Review
- Accuracy of quantitative viral secondary standards: a re-examination.Journal of clinical microbiology · 2024Article
- The risk factors associated with post-transplantation BKPyV nephropathy and BKPyV DNAemia: a prospective study in kidney transplant recipients.BMC infectious diseases · 2024Article
- MicroRNAs in infectious diseases: potential diagnostic biomarkers and therapeutic targets.Clinical microbiology reviews · 2023Review
- Unmasking the tissue-resident eukaryotic DNA virome in humans.Nucleic acids research · 2023Article
- Consensus Definitions of BK Polyomavirus Nephropathy in Renal Transplant Recipients for Clinical Trials.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- Matrix Matters: Assessment of Commutability among BK Virus Assays and Standards.Journal of clinical microbiology · 2022Article
- Review
- Translating genomic exploration of the familyiScience · 2022Article
- Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of Kidney Transplant Recipients.Annals of transplantation · 2022Article
- Classifying Polyomavirus Nephropathy: The "Banff" Initiative.Transplant international : official journal of the European Society for Organ Transplantation · 2022Article
- Pretransplantation seroreactivity in kidney donors and recipients as a predictive factor for posttransplant BKPyV-DNAemia.Frontiers in immunology · 2022Article
- Molecular diagnostic assays for COVID-19: an overview.Critical reviews in clinical laboratory sciences · 2021Review
- Article
- Donor-derived Cell-free DNA and the Prediction of BK Virus-associated Nephropathy.Transplantation direct · 2020Article
- Presentation of BK polyomavirus-associated hemorrhagic cystitis after allogeneic hematopoietic cell transplantation.Blood advances · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BK virus (BKV) is the infectious cause of polyomavirus-associated nephropathy. Screening guidelines for renal-transplant recipients define levels of viremia and viruria that are actionable for additional testing or intervention. However, standardized real-time PCR primers, probes, and standards are unavailable, and the extent of agreement among published assays is unknown. We compared seven TaqMan real-time PCR primer/probe sets (three designed at this institution, three described in the literature, and one purchased) in conjunction with two different standards to prospectively measure BKV titers in 251 urine specimens submitted to our clinical laboratory. We observed substantial disagreement among assays attributable both to features of primer and probe design and to choice of reference material. The most significant source of error among individual specimens was primer or probe mismatch due to subtype-associated polymorphisms, primarily among subtype III and IV isolates. In contrast, measurement of the most abundant subtypes (Ia, V, and VI) were typically uniform among all seven assays. Finally, we describe and validate a new clinical assay designed to reliably measure all subtypes encountered in our study population (Ia, Ic, III, IV, and VI). Consideration of available BKV sequence information in conjunction with details of subtype distribution allowed us to develop a redesigned assay with markedly improved performance. These results suggest that both accurate BKV measurement and the uniform application of BKV screening guidelines could be significantly improved by the use of standardized reference materials and PCR primers and probes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.